| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a7ddbd8c4a32d2796656a386fa814b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_388b6bbd48f518ade51be1c1bc27936d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate |
1994-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d61969651745163ef8b45ba83739a7fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35308517192edd25486d539168e37e2a |
| publicationDate |
1994-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9422457-A1 |
| titleOfInvention |
Method and composition for treatment of osteoporosis |
| abstract |
The combination of the following active ingredients for treating osteoporosis: (a) a pharmacologically-acceptable alkalinizing potassium salt which produces hydroxyl ions and is thereby capable of reducing the acidity of tissue fluids or urine and which is selected from the group consisting of potassium bicarbonate and potassium salts of carboxylic acids which are transformed to bicarbonate and thus alkalinize in vivo; and (b) an estrogen which is effective in the treatment of osteoporosis, in an amount of as little as 1/10 its normal recommended dose; the alkalinizing potassium salt being present in an amount such that the combination is substantially more effectie in treating osteoporosis than the same amount of the estrogen when independently administered. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1651246-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2002338277-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02078682-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1651246-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02078682-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-154323-A1 |
| priorityDate |
1993-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |